×
About 2,348,866 results
FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122973

Sep 19th, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar (glucose).1 Rybelsus® is the first and only glucagon-like peptide-1 (GLP-1) analog in a pill and a new option for adults with type 2 diabetes who are not achieving their ...

Psoriatic Arthritis - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK547710/

Sep 19th, 2019 - Psoriatic arthritis (PsA) is chronic inflammatory arthritis associated with psoriasis (PsO) and found in about 20 to 30% of such patients.[1] It shares many clinical features with other spondyloarthropathies and also rheumatoid arthritis (RA). It is usually seronegative, but a small percentage of patients may be positive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodi...

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
The New England Journal of Medicine; McMurray, J. et. al.

Sep 18th, 2019 - BACKGROUND In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 ...

Lipoprotein(a): The Next Promising CVD Risk Assessment Tool and Prevention Target Among the High-risk Population
https://www.acc.org/latest-in-cardiology/articles/2019/09/17/15/02/lipoprotein-a

Sep 17th, 2019 - After low density lipoprotein cholesterol (LDL-C) has been targeted to reduce cardiovascular disease (CVD) risk, other novel lipid biomarkers have become the center of attention of investigation, and on-going clinical trials are targeting these lipid markers trying to lower the so-called "residual CVD risk" in addition to conventional lipid-lowering therapy. Among them, serum lipoprotein(a) [Lp...

Alarming number of heart infections tied to opioid epidemic
https://newsroom.heart.org/news/alarming-number-of-heart-infections-tied-to-opioid-epidemic

Sep 17th, 2019 - An alarming number of people nationwide are developing infections of either the heart’s inner lining or valves, known as infective endocarditis, in large part, due to the current opioid epidemic. This new trend predominantly affects young, white, poor men who also have higher rates of HIV, hepatitis C and alcohol abuse, according to new research published in the Journal of the American Heart As...

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30311-0/fulltext
The Lancet Diabetes & Endocrinology; Lingvay, I. et. al.

Sep 16th, 2019 - Existing guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT2) inhibitors are increasingly used as second-line agents, direct comparisons between these treatments are insufficient. In the SUSTAIN 8 trial, we compared the...

U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
https://www.janssen.com/us-fda-approves-supplemental-new-drug-application-snda-erleada-apalutamide-treatment-patients

Sep 16th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved ERLEADA® (apalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).1 Today's approval follows FDA Priority Review Designation of the supplemental New Drug Application (sNDA) that was submitted in April 2019 and rev...

Frequently Asked Influenza (Flu) Questions: 2019-2020 Season | CDC
https://www.cdc.gov/flu/season/faq-flu-season-2019-2020.htm

Sep 15th, 2019 - What you need to know about the upcoming 2019-2020 influenza season in the United States.

Urinary Incontinence in Women: Evaluation and Management
https://www.aafp.org/afp/2019/0915/p339.html
American Family Physician;

Sep 14th, 2019 - Urinary incontinence is a common problem among women worldwide, resulting in a substantial economic burden and decreased quality of life. The Women's Preventive Services Initiative is the only major organization that recommends annual screening for urinary incontinence in all women despite low to insufficient evidence regarding effectiveness and accuracy of methods. No other major organization ...

Interventions to Prevent Perinatal Depression: Recommendation Statement
https://www.aafp.org/afp/2019/0915/od1.html
American Family Physician;

Sep 14th, 2019 - The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling interventions

Heart Failure Society of America Meeting
https://meeting.hfsa.org/

Sep 12th, 2019 - HFSA's Annual Scientific Meeting is intended for physicians, nurses, nurse practitioners, pharmacists, scientists, and health care professionals .

Coverage from the World Conference on Lung Cancer (WCLC) 2019
https://www.medscape.com/viewcollection/34905

Sep 12th, 2019 - World Conference on Lung Cancer (WCLC) 2019: Read clinically focused news coverage of key developments from WCLC 2019

FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy
http://ir.aimmune.com/news-releases/news-release-details/fda-allergenic-products-advisory-committee-votes-support-use

Sep 12th, 2019 - Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use of AR101 (proposed trade name PALFORZIA™) in children and teens with peanut allergy. PALFORZIA is a comp...

HeartFlow Announces FDA Clearance for HeartFlow Planner
https://www.heartflow.com/newsroom/heartflow-announces-fda-clearance-for-heartflow-planner

Sep 11th, 2019 - HeartFlow, Inc. today announced that it has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non-invasive, real-time virtual modeling tool for coronary artery disease (CAD) intervention. The HeartFlow Planner will enable interventional cardiologists to virtually model clinical scenarios vessel-by-vessel, explore treatment strategies for patients w...

Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
https://www.gsk.com/en-gb/media/press-releases/nucala-is-the-first-biologic-approved-in-the-us-for-six-to-11-year-old-children-with-severe-eosinophilic-asthma/

Sep 11th, 2019 - GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma. Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US.

GE Healthcare Receives FDA Clearance of First Artificial Intelligence Algorithms Embedded On-Device to Prioritize Critical Chest X-ray Review
https://www.genewsroom.com/press-releases/ge-healthcare-receives-fda-clearance-first-artificial-intelligence-algorithms

Sep 11th, 2019 - GE Healthcare today announced the Food and Drug Administration’s 510(k) clearance of Critical Care Suite, an industry-first collection of artificial intelligence (AI) algorithms embedded on a mobile X-ray device. Built in collaboration with UC San Francisco (UCSF), using GE Healthcare’s Edison platform, the AI algorithms help to reduce the turn-around time it can take for radiologists to review...

Advanced MRI brain scan may help predict stroke-related dementia
https://newsroom.heart.org/news/advanced-mri-brain-scan-may-help-predict-stroke-related-dementia

Sep 11th, 2019 - An advanced Magnetic Resonance Imaging (MRI) brain scan analysis in patients with stroke-related, small vessel disease helped predict problems with thinking, memory and even dementia, according to new research published in Stroke, a journal of the American Stroke Association, a division of the American Heart Association.

Mind and Body Approaches for Chronic Pain
https://nccih.nih.gov/health/providers/digest/ChronicPain-mindandbody

Sep 10th, 2019 - Some mind and body approaches may provide modest positive effects to help people manage daily variations in chronic pain; find out more here

Associations of Subjective Memory Complaints and Simple Memory Task Scores With Future Dementia in the Primary Care Setting
http://www.annfammed.org/content/17/5/412.full
Annals of Family Medicine;

Sep 9th, 2019 - PURPOSE Family physicians need simple yet comprehensive algorithms to discriminate between community-dwelling older persons who are at increased risk of dementia and those who are not. We aimed to investigate associations between incident dementia and responses to a single question regarding subjective memory complaints (SMC) combined with scores on 2 simple memory tests that are easy to use in...